206 related articles for article (PubMed ID: 24171686)
21. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Boonen A; Dirksen CD; Ben Sedrine W; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):19-28. PubMed ID: 23402442
[TBL] [Abstract][Full Text] [Related]
23. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
Thompson RN; Armstrong CL; Heyburn G
Bone; 2014 Apr; 61():44-7. PubMed ID: 24389366
[TBL] [Abstract][Full Text] [Related]
24. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
25. Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis-a case report.
Piponov HI; Goldstein JM; Eisenberg GM
Osteoporos Int; 2020 Nov; 31(11):2263-2267. PubMed ID: 32561954
[TBL] [Abstract][Full Text] [Related]
26. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
27. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
28. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
[TBL] [Abstract][Full Text] [Related]
29. Fracture Risk During and After Bisphosphonate Drug Holidays: A Matter of Methods?
Adams AL
Med Care; 2020 May; 58(5):417-418. PubMed ID: 32149922
[No Abstract] [Full Text] [Related]
30. A rational approach to management of alendronate-related subtrochanteric fractures.
Das De S; Setiobudi T; Shen L; Das De S
J Bone Joint Surg Br; 2010 May; 92(5):679-86. PubMed ID: 20436006
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Zafeiris CP; Stathopoulos IP; Kourkoumelis G; Gkikas E; Lyritis GP
J Musculoskelet Neuronal Interact; 2012 Dec; 12(4):262-4. PubMed ID: 23196269
[No Abstract] [Full Text] [Related]
32. Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
Sayed-Noor AS; Sjödén GO
Clin Orthop Relat Res; 2009 Jul; 467(7):1921-6. PubMed ID: 19198962
[TBL] [Abstract][Full Text] [Related]
33. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
34. Denosumab is an option for treatment of osteoporosis.
Simonelli C
Am Fam Physician; 2012 Dec; 86(11):992; author reply 994. PubMed ID: 23198660
[No Abstract] [Full Text] [Related]
35. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
36. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
Johnson GL
Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
[No Abstract] [Full Text] [Related]
37. VISUAL VIGNETTE.
Ayyoub S; Coyne C
Endocr Pract; 2018 Nov; 24(11):1020. PubMed ID: 30106629
[No Abstract] [Full Text] [Related]
38. [Osteoporosis].
Uelbelhart B; Rizzoli R
Rev Med Suisse; 2012 Jan; 8(324):109-10, 112-5. PubMed ID: 23185820
[TBL] [Abstract][Full Text] [Related]
39. Denosumab and atypical femur fractures.
Cating-Cabral MT; Clarke BL
Maturitas; 2013 Sep; 76(1):1-2. PubMed ID: 23835004
[No Abstract] [Full Text] [Related]
40. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
